ADVICENNE (EPA:ADVIC) | Finanzwire

Basculer en Français

10112	Companies
207299	Keywords
137391	Articles
109849	Press releases

Home
Companies
ADVICENNE

BRIEF

published on 03/26/2026 at 20:14, 3 days 14 hours ago

Advicenne presents its 2025 annual financial results

Financial Results Treasury Sales Growth Clinical Development Sibnayal®
BRIEF

published on 03/26/2026 at 20:14, 3 days 14 hours ago

Advicenne's 2025 Financial Overview: Mixed Results and Future Prospects

Revenue Growth FDA Approval Advicenne Financial Results 2025 Sibnayal®
PRESS RELEASE

published on 03/26/2026 at 20:09, 3 days 15 hours ago

Inside Information / News release on accounts, results
Advicenne reports its 2025 annual financial results, including a 18.7% increase in product sales, Sibnayal®'s growth in Europe, and the expected US Marketing Authorization. The company aims to extend its cash runway and restructure its balance sheet

Financial Results Advicenne Marketing Authorization Cash Runway Sibnayal
BRIEF

published on 01/19/2026 at 07:35, 2 months 11 days ago

Advicenne: FDA-approved marketing application for Sibnayal®

FDA ATRd Advicenna Sibnayal® PDUFA
BRIEF

published on 01/19/2026 at 07:35, 2 months 11 days ago

FDA Reviews Advicenne's Sibnayal® for U.S. Approval

FDA Advicenne Sibnayal® DRTA PDUFA Date
PRESS RELEASE

published on 01/19/2026 at 07:30, 2 months 11 days ago

Inside Information / Other news releases
FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026

FDA Advicenne Sibnayal DRTA PDUFA
BRIEF

published on 01/12/2026 at 07:35, 2 months 18 days ago

Renewal of the marketing authorization for Sibnayal® in the European Union

Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF

published on 11/04/2025 at 11:35, 4 months 25 days ago

Advicenne submits Sibnayal® to the US FDA

FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE

published on 11/04/2025 at 11:30, 4 months 25 days ago

Inside Information / Other news releases
Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months

Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF

published on 09/19/2025 at 18:05, 6 months 10 days ago

Advicenne: Half-year results in 2025 and outlook

Financial Results Outlook Turnover United States Sibnayal®

Accesswire

Published on 03/30/2026 at 09:05, 2 hours 7 minutes ago

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
Published on 03/30/2026 at 08:00, 3 hours 12 minutes ago

Portfolio Update
Published on 03/30/2026 at 08:00, 3 hours 12 minutes ago

Touchstone Exploration Announces an Operational Update
Published on 03/30/2026 at 00:15, 10 hours 57 minutes ago

$520,000 Cash R&D Tax Refund Received
Published on 03/29/2026 at 12:15, 22 hours 57 minutes ago

China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation

View all ACCESSWIRE

EQS Group

Published on 03/30/2026 at 11:07, 5 minutes ago

POS-Transaction in Own Shares
Published on 03/30/2026 at 11:03, 9 minutes ago

Aroundtown SA: Release of a capital market information
Published on 03/30/2026 at 11:02, 10 minutes ago

2026 Annual Shareholders' Meeting Season: EY and the Long Shadow of the Wirecard Scandal Investor advocates are criticizing the reappointment of EY as auditor for Deutsche Bank and Volkswagen. Pra
Published on 03/30/2026 at 11:00, 12 minutes ago

Cutting-edge breakthroughs take spotlight
Published on 03/30/2026 at 11:00, 12 minutes ago

MBT Unveils Next‑Gen Sustainable Solutions at MCE 2026

Les Echos

Published on 03/27/2026 at 19:06, 2 days 16 hours ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 2 days 16 hours ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 2 days 16 hours ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 2 days 17 hours ago

Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 2 days 17 hours ago

PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025

View all LES ECHOS COMFI WIRE